NO20060556L - Quetiapinmetabolitt - Google Patents
QuetiapinmetabolittInfo
- Publication number
- NO20060556L NO20060556L NO20060556A NO20060556A NO20060556L NO 20060556 L NO20060556 L NO 20060556L NO 20060556 A NO20060556 A NO 20060556A NO 20060556 A NO20060556 A NO 20060556A NO 20060556 L NO20060556 L NO 20060556L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutically acceptable
- symptoms
- bipolar
- disorders
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48436503P | 2003-07-02 | 2003-07-02 | |
PCT/GB2004/002783 WO2005002586A1 (en) | 2003-07-02 | 2004-06-28 | Metabolite of quetiapine |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060556L true NO20060556L (no) | 2006-04-03 |
Family
ID=33563981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060556A NO20060556L (no) | 2003-07-02 | 2006-02-02 | Quetiapinmetabolitt |
Country Status (20)
Country | Link |
---|---|
US (1) | US20050026900A1 (de) |
EP (1) | EP1644005B1 (de) |
JP (1) | JP2007516193A (de) |
KR (1) | KR20060082037A (de) |
CN (1) | CN1816339B (de) |
AR (1) | AR045004A1 (de) |
AT (1) | ATE477803T1 (de) |
AU (1) | AU2004253334A1 (de) |
BR (1) | BRPI0412127A (de) |
CA (1) | CA2531284A1 (de) |
DE (1) | DE602004028739D1 (de) |
ES (1) | ES2349091T3 (de) |
IL (1) | IL172616A0 (de) |
IS (1) | IS8283A (de) |
MX (1) | MXPA05013869A (de) |
NO (1) | NO20060556L (de) |
RU (1) | RU2005141060A (de) |
TW (1) | TW200509944A (de) |
UY (1) | UY28400A1 (de) |
WO (1) | WO2005002586A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003235435A1 (en) * | 2002-03-20 | 2003-10-08 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of quetiapine hemifumarate |
WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
JP2008526839A (ja) * | 2005-01-07 | 2008-07-24 | アストラゼネカ・アクチエボラーグ | 11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 |
US20060252744A1 (en) * | 2005-04-04 | 2006-11-09 | Burstein Ethan S | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents |
CA2603795A1 (en) * | 2005-04-14 | 2006-10-26 | Teva Pharmaceutical Industries Ltd. | Process for preparing quetiapine fumarate |
WO2007004234A1 (en) * | 2005-07-04 | 2007-01-11 | Usv Limited | A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE |
WO2007062338A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
CN101360724A (zh) * | 2005-11-18 | 2009-02-04 | 阿斯利康公司 | 盐形式 |
WO2008116144A1 (en) * | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Methods of treating mood disorders |
CN101360503A (zh) * | 2005-11-18 | 2009-02-04 | 阿斯利康公司 | 液体制剂 |
CN101360502B (zh) * | 2005-11-18 | 2012-03-14 | 阿斯利康公司 | 结晶形式 |
US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
EP2124908A4 (de) * | 2006-12-20 | 2011-04-27 | Astrazeneca Ab | Verbindungen und ihre verwendung |
JP2010514684A (ja) * | 2006-12-20 | 2010-05-06 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
JP2010514682A (ja) * | 2006-12-20 | 2010-05-06 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
JP5544024B2 (ja) * | 2009-12-31 | 2014-07-09 | ケムファーム・インコーポレーテッド | クエチアピンのアミノ酸結合体、その製造法及び使用法 |
ES2705233T3 (es) | 2010-03-11 | 2019-03-22 | Kempharm Inc | Conjugados de ácidos grasos de quetiapina, proceso para su fabricación y usos |
CN102552128B (zh) * | 2012-02-28 | 2013-09-18 | 陆荣政 | 一种富马酸喹硫平注射液及其制备方法 |
US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US5661184A (en) * | 1994-08-12 | 1997-08-26 | Eli Lilly And Company | Psychiatric agents |
AU5489299A (en) * | 1998-08-18 | 2000-03-14 | Sepracor, Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
US20040224942A1 (en) * | 2003-01-23 | 2004-11-11 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
-
2004
- 2004-06-28 WO PCT/GB2004/002783 patent/WO2005002586A1/en active Search and Examination
- 2004-06-28 BR BRPI0412127-9A patent/BRPI0412127A/pt not_active IP Right Cessation
- 2004-06-28 CN CN2004800188710A patent/CN1816339B/zh not_active Expired - Fee Related
- 2004-06-28 CA CA002531284A patent/CA2531284A1/en not_active Abandoned
- 2004-06-28 AT AT04743131T patent/ATE477803T1/de not_active IP Right Cessation
- 2004-06-28 ES ES04743131T patent/ES2349091T3/es active Active
- 2004-06-28 AU AU2004253334A patent/AU2004253334A1/en not_active Abandoned
- 2004-06-28 RU RU2005141060/15A patent/RU2005141060A/ru not_active Application Discontinuation
- 2004-06-28 KR KR1020057025264A patent/KR20060082037A/ko not_active Application Discontinuation
- 2004-06-28 EP EP04743131A patent/EP1644005B1/de active Active
- 2004-06-28 JP JP2006518324A patent/JP2007516193A/ja not_active Ceased
- 2004-06-28 MX MXPA05013869A patent/MXPA05013869A/es not_active Application Discontinuation
- 2004-06-28 DE DE602004028739T patent/DE602004028739D1/de active Active
- 2004-07-01 US US10/883,024 patent/US20050026900A1/en not_active Abandoned
- 2004-07-02 TW TW093120058A patent/TW200509944A/zh unknown
- 2004-07-02 AR ARP040102345A patent/AR045004A1/es not_active Application Discontinuation
- 2004-07-02 UY UY28400A patent/UY28400A1/es not_active Application Discontinuation
-
2005
- 2005-12-15 IL IL172616A patent/IL172616A0/en unknown
-
2006
- 2006-02-01 IS IS8283A patent/IS8283A/is unknown
- 2006-02-02 NO NO20060556A patent/NO20060556L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IS8283A (is) | 2006-02-01 |
RU2005141060A (ru) | 2006-07-27 |
CA2531284A1 (en) | 2005-01-13 |
US20050026900A1 (en) | 2005-02-03 |
AU2004253334A1 (en) | 2005-01-13 |
MXPA05013869A (es) | 2006-02-28 |
WO2005002586A8 (en) | 2006-02-09 |
CN1816339A (zh) | 2006-08-09 |
TW200509944A (en) | 2005-03-16 |
KR20060082037A (ko) | 2006-07-14 |
JP2007516193A (ja) | 2007-06-21 |
BRPI0412127A (pt) | 2006-08-15 |
ES2349091T3 (es) | 2010-12-27 |
EP1644005A1 (de) | 2006-04-12 |
WO2005002586A1 (en) | 2005-01-13 |
CN1816339B (zh) | 2010-12-15 |
ATE477803T1 (de) | 2010-09-15 |
EP1644005B1 (de) | 2010-08-18 |
IL172616A0 (en) | 2006-04-10 |
AR045004A1 (es) | 2005-10-12 |
UY28400A1 (es) | 2005-01-31 |
DE602004028739D1 (de) | 2010-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060556L (no) | Quetiapinmetabolitt | |
UY29924A1 (es) | Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables | |
DE60231826D1 (de) | Abgabevorrichtung für arzneimittel | |
GT200100183A (es) | Derivados de quinolina y quinazolina. | |
IL169358A (en) | A pharmaceutical formulation containing aripiprazole or its metabolite and serotonin reuptake inhibitors for the preparation of a medication to treat mood disorders | |
BRPI0414435A (pt) | métodos e reagentes para o tratamento de distúrbios imunoinflamatórios | |
BR0109161A (pt) | Beta-carbolinas substituìdas com atividade de inibição de ikb-quinase | |
BR0307050A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal | |
NO20065732L (no) | 4-Hydroksy-4-metylpiperidin-1-karboksylsyre (4-metoksy-7-morfolin-4-yl-benzotiazol-2-yl)-amid | |
DE60209511D1 (de) | Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten | |
ATE415968T1 (de) | 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen | |
GB0324654D0 (en) | Medicinal compounds | |
BRPI0813436A2 (pt) | Particulados de ácido (4,6-bis (dimetilamino)-2-(4-(4-(trifluorometil) benzamido)-benzil)pirimindin-5-il} acético, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação dos particulados. | |
UY27993A1 (es) | Derivados de 4-pirrolidino-fenil-bencil eter | |
BR0117009A (pt) | Composiçoes para utilização no tratamento de distúrbios associados a ige | |
BRPI0411176A (pt) | combinação farmacêutica consistindo de modafinil e outra droga | |
NO20043792L (no) | New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | |
MXPA05009986A (es) | Tratamiento de la enfermedad de alzheimer. | |
BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
BR0212167A (pt) | Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada | |
MY139551A (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
UY28401A1 (es) | Metabolito | |
ATE431147T1 (de) | Mittel zur behandlung des integrationsdysfunktionssyndroms | |
GT200600141A (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares | |
BR0212175A (pt) | Sal de bissulfato de uma 3-fenil-3-dimetilaminoalquil-4,4-dimetilpiperidin-2,6-di ona, composição farmacêutica, uso de um sal de bissulfato de uma 3-fenil-3-dimetilamino-alquil-4,4-dimetilpiperidin-2,6-d iona, e, método para o tratamento ou a profilaxia de um distúrbio afetivo relacionado com a tensão |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |